•  
  •  
 

Abstract

Sphagneticola trilobata (L.) Pruski is a medicinal plant widely used in traditional medicine for its anti-inflammatory, antimicrobial, antioxidant, hepatoprotective, wound healing, and CNS depressant effects. Despite its broad pharmacolo-gical potential, clinical application is limited due to a lack of mechanistic understanding, standardization, and clinical validation. This review aims to provide a comprehensive overview of the phytochemical composition, pharmacological activities, and therapeutic potential of S. trilobata, while highlighting research gaps and suggesting future directions for clinical translation. A systematic review of scientific literature, ethnobotanical sources, and pharmacological studies was conducted, focusing on phytochemical analysis, biological activity, toxicity, and potential applications in evidence-based medicine. Phytochemical studies reveal that S. trilobata contains flavonoids, terpenoids, sesquiterpene lactones, and phe-nolic compounds. Key constituents such as kaurenoic acid, grandiflorenic acid, and wedelolactone are associated with antioxidant, anti-inflammatory, hepatoprotective, antimicrobial, antidiabetic, and anticancer properties. However, there are gaps in understanding its pharmacokinetics, mechanisms of action, and clinical relevance. Although S. trilobata shows strong pharmacological promise, further research is needed to clarify molecular mechanisms, enhance bioavailability, and conduct well-structured clinical trials. These efforts are essential to support its integration into evidence-based and modern medicinal systems.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.